PKP2 screening and gene therapy for arrhythmogenic right-ventricular cardiomyopathy

Technology
In development
University
Scouted & summarized by Halo AI

NYU offers a licensable research platform and gene therapy development strategy for arrhythmogenic right ventricular cardiomyopathy (ARVC/D). The solution includes a validated cardiomyocyte-specific PKP2 knockout mouse model for drug screening and a gene therapy approach using functional PKP2 fragments. Inventors are seeking commercial partners for screening collaborations, vector development, and targeted cardiomyopathy programs to address the underlying genetic basis of this orphan disease.

Overview

This technology comprises a comprehensive, clinically relevant research platform and a therapeutic development strategy for arrhythmogenic right ventricular cardiomyopathy (ARVC/D), a rare and potentially lethal inherited heart disease. The platform utilizes a proprietary cardiomyocyte-specific, tamoxifen-activated Plakophilin-2 (PKP2) conditional knockout mouse model. This model effectively mimics the human disease, providing a validated template for screening small molecules, biologics, or gene therapies. Additionally, the technology includes a gene therapy approach focusing on delivering functional PKP2, with ongoing research into using minimal PKP2 fragments to improve delivery via adeno-associated virus (AAV) vectors while maintaining therapeutic efficacy.

Technical specifications
  • Validated PKP2-cKO murine model: Provides a platform to test agents against disease-causing PKP2 truncation mutations in a clinically relevant background.
  • Gene therapy strategy: Utilizes AAV-mediated delivery to target cardiomyocytes, correcting the genetic deficit and arresting disease progression.
  • Therapeutic candidates: Development focused on minimal functional PKP2 fragments (N-terminal, C-terminal, or armadillo repeat domains) to optimize AAV vector capacity and minimize potential off-target effects.
  • Model capabilities: Capable of demonstrating phenotypic rescue, including prevention of right ventricular dilation, reduction of arrhythmia burden, and improved survival.
Technology readiness level

The technology is at TRL 4. The foundational PKP2-cKO mouse model has been characterized and utilized in published preclinical studies demonstrating the potential for gene replacement therapy to arrest disease progression. Research into minimal functional PKP2 fragments is ongoing, with investigators seeking commercial partners for further development and refinement. While related gene therapy approaches have moved toward human trials, this specific...

Generated Aug 13, 2026. Please verify key information.

About New York University

New York University is a comprehensive private research university anchored in New York City, enrolling a large, diverse student body and operating a global network of campuses. Corporate engagement is enabled by co‑located engineering and computing hubs in Brooklyn and Manhattan with shared labs and facilities for prototyping and field pilots. Integration with a major hospital system supports clinical translation, IRB processes, and access to real‑world data under stringent governance. Proximity to leading industries and a mature sponsored‑research function streamline scoping, NDAs, MSAs, and talent pipelines. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DOD, and a dedicated technology transfer office manages IP, licensing, and startup creation.

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.